MSCA programme in HE

Marie Skłodowska-Curie Actions

The Marie Skłodowska-Curie Actions fund excellent research and innovation and equip researchers at all stages of their career with new knowledge and skills, through mobility across borders and exposure to different sectors and disciplines. The MSCA help build Europe’s capacity for research and innovation by investing in the long-term careers of excellent researchers.

The MSCA also fund the development of excellent doctoral and postdoctoral training programmes and collaborative research projects worldwide. By doing so, they achieve a structuring impact on higher education institutions, research centres and non-academic organisations.

The MSCA promote excellence and set standards for high-quality researcher education and training in line with the European Charter for Researchers and the Code of Conduct for the recruitment of researchers.

There are 5 types of MSCA targeting different objectives.

  • Doctoral Networks (DN)
    Supporting programmes to train doctoral candidates in academic and non-academic organisations.
  • Postdoctoral Fellowships (PF)
    Supporting career perspectives and excellence of postdoctoral researchers.
  • Staff Exchanges (SE)
    Encouraging collaborations between organisations through staff exchanges.
  • COFUND
    Co-funding of regional, national and international programmes.
  • MSCA and Citizens
    Bringing research and researchers closer to the public at large.

More information on the Marie Skłodowska-Curie Actions is available here.

MSCA Doctoral Networks (DN) Projects

— 5 Items per Page
Showing 1 - 5 of 7 results.

MSCA Postdoctoral Fellowships (PF) projects

— 5 Items per Page
Showing 1 - 5 of 19 results.

MSCA COFUND projects

Evaluating the potential of targeting 2- AG hydrolytic enzymes MAGL and ABHD6 as novel therapeutic strategy in multiple sclerosis

Specific programme: ARSEP Foundation on Multiple Sclerosis Research 2016
UPV/EHU Partner Status: Research project grantee
UPV/EHU PI: Susana Mato
Project start: 01/11/2015
Project end:   30/11/2017
 

Brief description:  Our working hypothesis, based on previously obtained results (Bernal-Chico et al., 2015), is that is that attenuation of 2-AG hydrolysis may be a useful strategy for the treatment of myelin diseases. The general objective of this project is to rationally evaluate the potential of targeting the serine hydrolases MAGL and ABHD6 to treat MS. With this aim we will compare the ability of drugs that inhibit each enzyme to attenuate different pathological features of the disease as well as to promote repair mechanisms both in vitro and in vivo. In addition we will explore the appearance of molecular adaptations associated to the chronic use of MAGL or ABHD6 inhibitors and that may limit the efficacy of the long-term efficacy of these compounds.